REG - Scancell Hlds - Scancell to attend upcoming conferences

Scancell HoldingsAnnouncement

02/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240902:nRSB4535Ca&default-theme=true

RNS Number : 4535C  Scancell Holdings Plc  02 September 2024

2 September 2024

 

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell Announces its Attendance at Upcoming Conferences

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer, is pleased to confirm that it will be presenting at,
and will also attend, several upcoming conferences and events in September,
October and November 2024. Presentations at these high-profile conferences
follow the significant recent progress that Scancell has made in both
pre-clinical and clinical development.

 

These include:

 

·      ADC & Radiopharmaceuticals Pharma & Biotech Partnering
Summit (https://adc-partnering.com/) taking place in Boston, Massachusetts,
USA from 9-10 September.

Mandeep Sehmi, Head of Business Development, will be attending the conference.

 

·      ESMO Congress 2024
(https://www.esmo.org/meeting-calendar/esmo-congress-2024) taking place in
Barcelona, Spain from 13-17 September

Dr Nermeen Varawalla, Chief Medical Officer, and Dr Robert Miller, Medical
Director, will be attending the conference.

 

·      Vaccines & Immunotherapies Online Symposium
(https://oxfordglobal.com/biologics/events/vaccines-immunotherapies-online-symposium)
taking place virtually on Thursday, 26 September.

Samantha Paston, Head of Translational Research, will be presenting.

Title: Phase 2 clinical trial, a DNA cancer vaccine, SCIB1, in patients with
advanced unresectable melanoma receiving nivolumab + ipilimumab

Time: 4.20pm BST

 

·      Festival of Biologics
(https://www.terrapinn.com/conference/festival-of-biologics/index.stm) taking
place in Basel, Switzerland from 15-17 October.

Prof Lindy Durrant, Chief Executive Officer and Chief Scientific Officer, will
be presenting.

Session Title: Therapeutic Vaccine Development

Title: Clinical update on the DC targeting melanoma vaccine, SCIB1 and the
Modi-1 vaccine targeting citrullination

Date and Time: Wednesday, 16 October at 5.30pm CEST

 

·      16 (https://www.pegsummiteurope.com/) (th
(https://www.pegsummiteurope.com/) ) Annual PEGS Europe
(https://www.pegsummiteurope.com/) taking place in Barcelona, Spain and
virtually from 5-7 November.

Mireille Vankemmelbeke, Principal Scientist, will be presenting.

Session Title: Antibody-Based Cancer Therapies: Novel Targets

Title: Fucosyl-GM1: A Versatile Target for SCLC Therapy

Date and Time: Tuesday, 5 November at 5.05pm CEST

 

If you would like to arrange a meeting with management, please contact
commercial.enquiries@scancell.co.uk
(mailto:commercial.enquiries@scancell.co.uk) .

 

-ENDS-

 

 For further information, please contact:

 Scancell Holdings plc                                                    +44 (0) 20 3709 5700
 Dr Jean-Michel Cosséry, Non-Executive Chairman
 Professor Lindy Durrant, CEO

 Panmure Liberum Limited (Nominated Advisor and Joint Broker)             +44 (0) 20 7886 2500
 Emma Earl, Freddy Crossley, Will Goode, Mark Rogers (Corporate Finance)
 Rupert Dearden (Corporate Broking)
                                                                          +44 (0) 20 3705 9330

 WG Partners LLP (Joint Broker)

 David Wilson/Claes Spang/Satheesh Nadarajah/Erland Sternby

 ICR Consilium                                                            +44 (0) 20 3709 5700
 Mary-Jane Elliott/Angela Gray/Lindsey Neville                            scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer. The Company is building a pipeline of innovative products by utilising
its four technology platforms: Moditope® and ImmunoBody® for vaccines and
GlyMab® and AvidiMab® for antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope® and
ImmunoBody®) this includes citrullination and homocitrullination of proteins,
whereas its mAb portfolio targets glycans or sugars that are added onto
proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and
their ability to directly kill tumour cells (AvidiMab®).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQKDBDKBKBOCK